We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
GDR do not have an official speaking slot (at least not from what I can see)
That may work in GDRs favour however, if A Cytiva spokesman is discussing the test, for example.
Avct & Abingdon do have presenters, amongst a few others.
Mags, It was when I originally invested back in 2016, not a covid to be seen.... Diagnostics has been a poor sector for many years, COVID has just shown people how important it is. A POC play in this market is very well placed, one that has already been proven with other markets even better. What sales multiple does the current MC support? Once we have sales it will be easier to value.
Can’t see GDR where does it start?
@magsy
interesting thought
I think obviously most of you wouldn't be here if it wasn't for covid....
would the company be in the finacial position it is now with out covid ....no ofc not
has this impacted the share price ofc it has.
but when the share price rocketed it was a who approval for Hepc which sent it rising not a covid product
you could argue that interest was because of covid but the share price has risen in the past to levels above this on none covid products alone so impossible to tell.
being honest magsy neither of us is wrong and neither of us is totally right. It is a balance of the two things and the present situation. We can't single one thing out and point at one thing and say there is your answer.
Mmmm - BB Heroes, apologies hadn’t listened ahead of posting...must have missed, let’s see if he corrects
Also, without covid, do you think the mcap would be where it is today?
Would you say that sentiment around shares like GDR at this current time is driven primarily from covid based activities?
https://www.share-talk.com/pharma-special-bulletin-board-heroes-tuesday-27th-october-2020/#gs.jssrvz
GDR included
or you could say at least half of what i mentioned was not cd 19 related.
who approval for HepC test was huge.
with the UN and WHO targeting Hepc as there are now cheap and effective ways of treating to be first to market with a POC test certainly has value.
Yes, Grim, so most of that is related to covid sales ultimately, so we are on the same page.
It's painfully obvious that the high share prices of companies like GDR is based upon the potential success of their covid products. Look at all the other covid based shares, the pattern is clear to see.
@magsy had no idea what the conversation was
was just pleased to see you :)
but will give it a go
£5M US DOD order this quarter
we know some sales have been made.
we have £1 M presales to areas needing approvals
we are expecting approvals from who, fda and india that we know of
we have a raft of products which are now market ready, antibiotic hearing loss test, HepC test, Covic 19 PCR test (with some nice features) a 15 minute covid 19 salvia based POC test under development for sale in first Quarter next year.
we have a proven POC kit which is good enough for the US Dod to invest in which could in time using a number of different samples test for almost any pathogen.
We have partnered with two companies under the danher company ownership to produce a rapid cd 19 testing platform which the us government has invested in to increase testing by (i hope i got this right) 100k a day (day or week not sure which) that is potentially £1M in income for GDR.
now that seams like pretty good value for £66M but i sure i have missed a few
Wasn’t everyone saying the other day that unless we get some sales news, the sp won’t be going anywhere??? Surely these people don’t think sales are priced in??
Not sure we do, the value today is what shareholders are prepared to pay, with no sales and no forecasts its a bet that sales will force the share price up... how much is built in todays price is anyones guess, but the fall in share price suggests most is now priced out.
pheww finally we agree.... now green light this SP!!
Exactly my point!
We agree then.
It's semantics, as soon as sales come in we are expecting this to rise not stay still
Mags, the same reason we are not valued at £0 with no sales booked
Grim, feel free to help explain why we are valued at £66m if no covid sales are priced in.
The mcap increase in 2020 could be due to the product, not sales. GDR didn’t have this product before Covid.
When the share price reached £3 in May that was, I think, with sales priced in. As expectations of sales dampened the SP went down. That’s why I think current SP reflects a good product with no sales. If sales orders confirmed then we could see £3+ which is what the SP reached in April on expectation but no confirmation of sales.
But we shall see...
Ah there he is :)
that is more like it :)
An expectation of sales is almost definitely still priced in. GDR received £1m in revenue last year, and we are sitting at around £66m mcap right now.
I tend to agree Radley, sales are not priced in, in fact the gradual fall in SP is testament to that. With sales, GDRs share price is a multiple of todays price, the partners GDR have chosen should be able to generate significant test volume. Exciting times.
118 being paid again
GDR have a product, and a market cap of £60m.
NCYT too have a product, and a marker cap of £800m.
The difference between the two companies is that NCYT, as first movers, have sales orders.
I assume investors in GDR think GDR too will soon have confirmed orders. If that happens then then share price will go up accordingly. Even if GDR market cap is half of NCYT that would make SP around £6.
What is reassuring is that the current share price doesn’t have sales orders already priced in.
Looking strong again 4 x 1.5k bid vs ask